Kennondale Capital Management LLC bought a new stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Free Report) in the fourth quarter, HoldingsChannel.com reports. The firm bought 151,280 shares of the biotechnology company’s stock, valued at approximately $755,000.
A number of other institutional investors also recently modified their holdings of the business. State Street Corp boosted its position in shares of Aldeyra Therapeutics by 1.7% in the third quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock valued at $5,249,000 after acquiring an additional 16,188 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Aldeyra Therapeutics in the fourth quarter valued at about $3,628,000. Jacobs Levy Equity Management Inc. boosted its position in shares of Aldeyra Therapeutics by 163.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after acquiring an additional 295,864 shares during the period. Woodstock Corp boosted its position in shares of Aldeyra Therapeutics by 7.8% in the fourth quarter. Woodstock Corp now owns 194,919 shares of the biotechnology company’s stock valued at $973,000 after acquiring an additional 14,113 shares during the period. Finally, Barclays PLC boosted its position in shares of Aldeyra Therapeutics by 280.1% in the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock valued at $353,000 after acquiring an additional 48,313 shares during the period. Institutional investors own 59.71% of the company’s stock.
Aldeyra Therapeutics Trading Down 8.7 %
ALDX opened at $6.31 on Tuesday. Aldeyra Therapeutics, Inc has a twelve month low of $2.75 and a twelve month high of $7.20. The company has a 50-day simple moving average of $5.81 and a 200 day simple moving average of $5.48. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Monday, March 3rd.
View Our Latest Report on Aldeyra Therapeutics
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Further Reading
- Five stocks we like better than Aldeyra Therapeutics
- What is a buyback in stocks? A comprehensive guide for investors
- Can TikTok Stock Picks Really Make You Rich?
- What is the Hang Seng index?
- The “Quality” Rotation: Back to Basics Investing
- How to Invest in the Best Canadian Stocks
- Occidental Petroleum: 4 Reasons to Love These Prices
Want to see what other hedge funds are holding ALDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Free Report).
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.